Cynthia Smith
Direktor/Vorstandsmitglied bei AKEBIA THERAPEUTICS, INC.
Vermögen: 181 114 $ am 30.04.2024
Aktive Positionen von Cynthia Smith
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AKEBIA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.08.2018 | - |
Independent Dir/Board Member | 28.08.2018 | - | |
SPERO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.03.2019 | - |
Independent Dir/Board Member | 19.03.2019 | - | |
PROTARA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2021 | - |
Independent Dir/Board Member | 01.01.2021 | - | |
AGIOS PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 11.08.2022 | - |
Independent Dir/Board Member | 11.08.2022 | - | |
French-American Foundation | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Cynthia Smith
Ehemalige bekannte Positionen von Cynthia Smith
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
DICERNA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 13.08.2018 | 28.12.2021 |
Independent Dir/Board Member | 13.08.2018 | 28.12.2021 | |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Direktor/Vorstandsmitglied | 01.11.2016 | 01.07.2017 |
Independent Dir/Board Member | 01.11.2016 | 01.07.2017 | |
ZS PHARMA INC | Corporate Officer/Principal | 01.06.2013 | 01.12.2016 |
AFFYMAX, INC. | Corporate Officer/Principal | 01.10.2008 | 01.03.2013 |
░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Cynthia Smith
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Eagleton Institute of Politics | Graduate Degree |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 14 |
Operativ
Director/Board Member | 7 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 3 |
Sektoral
Health Technology | 10 |
Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
AFFYMAX, INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
AKEBIA THERAPEUTICS, INC. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
PROTARA THERAPEUTICS, INC. | Health Technology |
AGIOS PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
ZS Pharma, Inc.
ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
French-American Foundation |
- Börse
- Insiders
- Cynthia Smith
- Erfahrung